Answers are grounded in this paper and cite their sources.
The complexation of appropriate organoplatinum compounds by water‐soluble polymers has the potential to provide a time‐release formulation which might afford a substantial reduction in the severity of side effects associated with use of organoplatinum antitumor agents. Both poly‐(N‐vinylpyrrolidone)(PVP) and poly(N‐vinyl‐5‐methyl‐2‐oxazolidone)(PVOM) form stable, biologically active, molecular complexes with organoplatinum compounds containing polar aromatic ligands. Platinum compounds suitable for complexation by these polymers include cis‐dichloro(4‐substituted o‐phenylenediamine)platinum(II), 4‐substitutedcatecholato(1,2‐diaminocyclohexane)platinum(II), and 4‐substitutedphthallato(1,2‐diaminocyclohexane)‐platinum(II) compounds.
No takes yet. Share an insight, caveat, or question.
Howell et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: